Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note released on Monday morning,Benzinga reports. D. Boral Capital currently has a $27.00 price objective on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Medicus Pharma presently has an average rating of “Hold” and an average target price of $23.50.

Medicus Pharma Price Performance

Shares of MDCX stock opened at $0.49 on Monday. Medicus Pharma has a 1 year low of $0.37 and a 1 year high of $8.94. The firm has a fifty day moving average price of $1.22 and a 200-day moving average price of $1.84. The company has a market cap of $12.40 million, a price-to-earnings ratio of -0.23 and a beta of -1.58.

Institutional Trading of Medicus Pharma

Several institutional investors and hedge funds have recently modified their holdings of MDCX. Private Advisor Group LLC lifted its stake in shares of Medicus Pharma by 3.8% during the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares in the last quarter. Osaic Holdings Inc. increased its stake in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after buying an additional 9,000 shares in the last quarter. Jane Street Group LLC bought a new stake in Medicus Pharma during the second quarter valued at about $41,000. Commonwealth Equity Services LLC raised its holdings in Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after acquiring an additional 17,611 shares during the period. Finally, May Hill Capital LLC lifted its position in shares of Medicus Pharma by 100.0% in the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after acquiring an additional 17,811 shares in the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.